Novel Neoantigen Screening Tool:  QuickSwitch™ Custom Tetramer Kits

A rapid high throughput and user friendly system for creating new tetramer specificities. Tetramers resulting from peptide exchange with selected peptides can be used for immune monitoring.

Useful for research involving cancer neoantigens, infectious agents and many other research areas.

Learn more about our QuickSwitch™ products.

• Share your review – write about your experience using an MBLI product and receive an award. Terms and Conditions apply.

MBL International is here to work with you and advance your unique research needs using custom services. We can help with Immuno-monitoring services using MHC Tetramers and Cytokines.  Contact us today for more information.

MBL International will be exhibiting at the following shows:

Nov 6 – 10: SITC 2019 in National Harbor, MD

Press Release

July 30, 2019 – Des Plaines, IL – We are pleased to inform you that MBL International has sold our stake in BION Enterprises to the AESKU Group effective July 30, 2019.  BION Enterprises manufactured IFA Slides and component kits and handled commercial transactions for our In Vitro Diagnostics line of products. Changes to MBL’s business strategy, as well as changing market dynamics, drove our decision to divest the IFA business.

MBL International will now focus our efforts on providing solutions for researchers working in immunology, immune-oncology, oncology, and autoimmune disease areas. As a JSR Life Sciences Company, MBLI is committed to improve the probability of success, decrease timelines, and increase the efficacy of biologics-based therapies for the benefit of patients.

We appreciate your business over the years and look forward to our continued partnership in the years to come.

Click here to view a copy of the letter and products transferred to new owner.

Jan. 23, 2018 – Sunnyvale, CA – JSR Life Sciences, the life sciences-focused business unit of JSR Corporation, announced today that it has appointed Dr. Nalini Murdter as the President and Chief Executive Officer of MBL International (MBLI) effective immediately.

Read More

May 22nd, 2017: MEDICAL & BIOLOGICAL LABORATORIES Co., Ltd. (MBL) announced that it has entered into a collaboration agreement with the p53 Laboratory, Agency for Science, Technology and Research (A*STAR) in Singapore to establish the novel screening technology which accelerates the drug discovery targeting Protein-Protein Interactions (PPIs).

February 28th, 2017: MEDICAL & BIOLOGICAL LABORATORIES Co., Ltd. concludes a patent licensing agreement with the University of Toyama concerning a rapid antibody production technique

• Afamin/Wnt3a Culture Medium – New serum free culture medium that allows for long term organoids to be made possible.
• T-Select Human MR1 Tetramer – Use to recognize human MAIT cells binding to MR1/MR1-ligand complex
• Fluoppi Protein-Protein Interaction – Visualize and Screen PPI’s with 18 new pre-made vector sets of popular oncology targets
• TransFix® – A patented stabilization solution that is easy to use and preserves cells and cellular antigens for up to 14 days prior to analysis

• New tetramer for vaccine research targeting Tuberculosis and Ag85B specific T-cells

  Tue, 23 Jul 2019 17:00:00 GMTBy: bindi.doshi@mblintl.com (Bindi M. Doshi, PhD)

  Tuberculosis (TB) is caused by the Mycobacterium tuberculosis and usually targets the lungs.  This disease is spread when an infected person sneezes or coughs, thereby releasing small droplets into the air and passing to a new individual. When left untreated, death can occur. Thankfully, there is a vaccine for TB called Bacille Calmette-Gurin (BCG) and is often given to young children.  This vaccine has been shown to last 15 years. There is some doubt about the efficacy of the BCG vaccine in adult pulmonary TB1,2.  For this reason, more research needs to be done to provide a safe and effective TB vaccine for adults.
  Antigen (Ag) 85 is gaining interest among vaccine development research.  Ag85 is preserved in Mycobacterium and allows bacteria to evade the host immune response by preventing mechanisms involved in terminating the infection3.  Research continues to uncover exactly how Mycobacterium tuberculosis persists and remains in an infected person while evading the immune system.  New advances in immunology are giving researchers a greater picture for how the immune response is manipulated by this bacteria.  It is clear that with greater understanding of how the human immune response system functions and how different infections manipulate this system, that targeted therapies, including vaccines, can be developed to combat the infection successfully.
  MBL International is pleased to announce the launch of our new tetramer targeted to Ag85B-specific T cells for murine studies. As always, our team is on hand for any question or request that you may have.

  Product Code
  Target
  Conjugate

  TS-M719-1
  I-Ab Mtb Ag85B240-254 Tetramer-FQDAYNAAGGHNAVF
  PE

  TS-M719-2
  I-Ab Mtb Ag85B240-254 Tetramer-FQDAYNAAGGHNAVF
  APC

  (1) Davenne,T., & McShane, H. (2016). Why don’t we have an effective tuberculosis vaccine yet?. Expert review of vaccines, 15(8), 1009–1013. doi:10.1586/14760584.2016.1170599
  (2) Andersen, P., & Doherty, T.M. (2005). The success and failure of BCG – implications for a novel tuberculosis vaccine. Nature Reviews Microbiology,3(8), 656-662. doi:10.1038/nrmicro1211
  (3) Babaki, M. K., Soleimanpour, S., & Rezaee, S. A. (2017). Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: Biology, immune-pathogenicity, applications in diagnosis, and vaccine design. Microbial Pathogenesis, 112, 20-29. doi:10.1016/j.micpath.2017.08.040 Read more

• Why protein phosphorylation is crucial in disease research

  Thu, 13 Jun 2019 17:00:00 GMTBy: bindi.doshi@mblintl.com (Bindi M. Doshi, PhD)

  Protein phosphorylation is quintessential for specific pathways to function.  This function can be influenced by internal or external factors.  It is a reversible action with the involvement of kinases and phosphatases1.  This activity is crucial in the cell cycle, apoptosis, and signal transduction pathways.  If a protein is phosphorylated or dephosphorylated when it shouldn’t be, there can be severe disruptions to the cellular pathway.  At times, the phosphorylation state can be the cause of a disease.  This has been found in degenerative diseases, cancers, and various pathways involving the immune system2.  For instance, kinase inhibitors have been successful in cancer treatments. 
  Enzymes control phosphorylation.  Kinases function to add phosphate groups to proteins and phosphatases function to remove phosphates.  Typically, phosphorylation occurs on serine, threonine, or tyrosine residues. This process can be very quick or it can take many hours. It results in a conformational change which either activates or inactivates protein activity. Read more

• QuickSwitch, a tool for adoptive T cell transfer

  Wed, 24 Apr 2019 17:00:00 GMTBy:

  Our understanding of how the immune system responds to cancer has increased by leaps and bounds in the past two decades, allowing us to develop a new approach to fight cancer that uses the power of the body’s own immune system to prevent, target, control, and eliminate the disease. Collectively, this technique of battling cancer is known as cancer immunotherapy. Such an approach encompasses many methods from broad ones like applying immune checkpoint blockers (ICB) or using monoclonal antibodies (mAbs) that target known cancer antigens to more personalized ones like adoptive T cell transfer including the use of Chimeric antigen receptor (CAR) T cells.
  It is this personalized immunotherapy approach that has sparked a great deal of interest among researchers. This method involves the extraction of a patient’s T cells and the subsequent stimulation of the rare T cells populations that can fight cancer with specific antigens. For this form of therapy to work there needs to be an exact knowledge of the peptide sequences derived from tumor cells (neo-epitopes) that can be used to artificially stimulate a patient’s T cells to fight them.
  Previously, we have described how by using the QuickSwitchTM Quant Platform peptides, they can be tested for their ability to bind MHC Class I molecules. This test does not involve prediction algorithms or large swaths of data with a great deal of false positives but provides an in vitro result of whether or not the peptide can be presented on the MHC molecule in about 8 hours. It is our hope that by using our kit, researchers will be able to discover and validate neoantigen peptide sequences more effectively, which would open up new ways for adoptive T cell transfer in cancer immunotherapy. Read more

View All